HC Wainwright Issues Negative Estimate for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright lowered their Q3 2027 EPS estimates for Rhythm Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.33 for the quarter, down from their previous estimate of $0.42. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

A number of other research analysts have also recently issued reports on the company. Royal Bank Of Canada decreased their target price on Rhythm Pharmaceuticals from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, January 22nd. Morgan Stanley decreased their price objective on Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a research report on Tuesday. Bank of America lowered their target price on Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Citigroup dropped their target price on shares of Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.13.

Rhythm Pharmaceuticals Trading Down 2.1%

Shares of Rhythm Pharmaceuticals stock opened at $85.86 on Thursday. The company has a market capitalization of $5.86 billion, a PE ratio of -27.61 and a beta of 2.06. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20. The stock’s fifty day simple moving average is $99.45 and its 200 day simple moving average is $102.69.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. During the same period last year, the firm posted ($0.72) earnings per share. The business’s quarterly revenue was up 36.9% compared to the same quarter last year.

Insider Transactions at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 27,267 shares of company stock worth $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Rhythm Pharmaceuticals by 39.2% in the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after purchasing an additional 1,407,313 shares in the last quarter. RA Capital Management L.P. lifted its position in Rhythm Pharmaceuticals by 17.3% during the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after buying an additional 985,478 shares in the last quarter. Alliancebernstein L.P. lifted its position in Rhythm Pharmaceuticals by 1,493.8% during the 3rd quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock worth $98,938,000 after buying an additional 918,212 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Rhythm Pharmaceuticals by 445.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock worth $49,513,000 after buying an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors acquired a new position in shares of Rhythm Pharmaceuticals during the 3rd quarter worth about $60,417,000.

More Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.